Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders ; volume:8 ; number:1 ; day:5 ; month:9 ; year:2018 ; pages:1-9 ; date:12.2018
Scientific reports ; 8, Heft 1 (5.9.2018), 1-9, 12.2018
- Urheber
-
Hall, Sara
- Beteiligte Personen und Organisationen
-
Janelidze, Shorena
Surova, Yulia
Widner, Håkan
Zetterberg, Henrik
Hansson, Oskar
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-31517-z
- URN
-
urn:nbn:de:101:1-2018102023105430362946
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hall, Sara
- Janelidze, Shorena
- Surova, Yulia
- Widner, Håkan
- Zetterberg, Henrik
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Factors associated with fear of falling in people with Parkinson’s disease
The clinical significance of 10-m walk test standardizations in Parkinson’s disease
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
External validation of a 3-step falls prediction model in mild Parkinson’s disease